Hear from Dr. Craig Cole the results of the phase 1 study in 2019 with Selinexor, Carfilzomib and dexamethasone. How did this trial affect options for relapsed/refractory myeloma patients? What role does selinexor play in relapsed myeloma? Come with your questions about this trial and myeloma treatment.
Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Craig Emmitt Cole, M.D. is a board-certified Hematologist who received his Bachelor of Science degree in physiology at Michigan State University and the College of Lyman Briggs, in East Lansing Michigan. Dr. Cole went on to receive his doctoral degree at the Ohio State University College of Medicine in Columbus, Ohio. He completed his Internal Medicine Residency and Hematology/Oncology Fellowship at the University of Michigan Health System, Ann Arbor, Michigan. Dr. Cole subsequently had a post-fellowship laboratory research position at the Jerome Lipper Multiple Myeloma Center of Medicine at Dana-Farber Cancer Institute in Boston, Massachusetts. This opportunity then led to him becoming an attending hematologist at Gundersen Health System in La Crosse, Wisconsin for 9 years. There he was an instructor for both the medical and nursing schools of the western campus of the University of Wisconsin School of Medicine and Public Health. He also served as Affiliate Faculty Member of Graduate Community Health Programs and Assistant Professor (Adjunct) at the University of Wisconsin-La Crosse, Department of Health Professions. While in Wisconsin, his clinical research interest was in multiple myeloma, malignant hematology, clinical apheresis, and patient reported outcomes in hematology. He then returned to the University of Michigan Rogel Cancer Center in Ann Arbor, Michigan as an Assistant Professor in the Division of Hematology/Oncology with his primary clinical and research interest being in multiple myeloma. In May of 2019, he returned to Michigan State University College of Human Medicine at Breslin Cancer Center as the Director of Clinical Research in Hematology/ Oncology and Multiple Myeloma. Dr. Cole has been participated in over 50 clinical trials in Multiple Myeloma and Malignant Hematology. He is a member of the International Myeloma Working Group, International Myeloma Society and the American Society of Hematology; he has published in national journals and presented at the American Society of Hematology International Myeloma Workshop, and the American Society for Apheresis meetings. He has lectured across the United States to patients, researchers and clinical providers in multiple myeloma, plasma cell dyscrasias, and disparities in cancer care. He has won awards for his work in student and resident teaching, multiple myeloma research, and patient advocacy. Dr. Cole has always had a strong commitment to equity of cancer care, patient empowerment, and community education by working with several local and national patient advocacy associations to bring the good news of myeloma research to everyone.
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
+1 800 709 1113